Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (17129)	3/10/1998 10:39:00 PM
From: tonyt	Read Replies (1) \| Respond to of 32384

Fine, lets not let it rest. The person who posted the original question has verified what we all knew to be true -- he raised the question 'Did ligand take the money and run or did they select a drug?', to which he received the response ""Watch what happens on Monday!", now that response was a bit vague, so he asked "Watch what happens on Monday! as in something great is going to happen or as in cover your head cuz the sky is going to fall?", to which the clarification was "The former." So, andy, please tell us,what was this great thing that was supposed to happen yesterday?

To: Andrew H who wrote (17129)	3/10/1998 10:42:00 PM
From: tonyt	Respond to of 32384

Stunning Biotech Developments or Stunned Biotech Investors? ====================================================== SAN FRANCISCO--(BUSINESS WIRE)--March 10, 1998--Many biotechnology investors have been stunned more by the absence of profits in their investments than by medical progress in the sector, so finding the gems requires more knowledge than ever. According to Investor's Business Daily's rankings, the sector has hovered in mediocrity for better than a year. Last week the group of 178 stocks sat at 77th among 197 industry groups and this week slipped to 95th. Six months ago the group ranked 109th. By contrast, the drug group with Merck (NYSE:MRK), Warner-Lambert (NYSE:WLA), Abbott Laboratories (NYSE:ABT), Schering-Plough (NYSE:SGP) and Pfizer (NYSE:PFE) -- which many times drive development at biotechnology firms -- has soared 18.5% since January. Why the disparity? Fund manager Mike Yellen of GT Global Healthcare Funds blames the lack of quality stocks in the biotechnology group. "There are too many companies without real products and real opportunities that have been taken public by Wall Street over the past couple years," he says. Finding the good ones -- or firms that might be absorbed -- is tricky. "We think the sector will continue to see consolidation along the lines of Arris Pharmaceuticals (NASDAQ:AXYS) and Sequana," said Tim Quast, chief operating officer of Informed Investors. "Opportunities for deals with major drug companies are thinning, and that means firms must combine forces or change their business plans like Cypros (AMEX:CYP) and Genta (NASDAQ:GNTA) have done to finance drug-development in-house." Cypros and Genta are among the biotech companies presenting on March 14 at the 2nd San Diego Informed Investors Biotech Forum. The conference runs from 8am-12:45pm at the Mission Valley Radisson. Also presenting are Trega Biosciences (NASDAQ:TRGA) and Aurora Biosciences (NASDAQ:ABSC), which among them have leveraged combinatorial chemistry libraries into agreements with Warner-Lambert, Eli Lilly (NYSE:LLY), Bristol-Myers Squibb (NYSE:BMY) and others. Vical (NASDAQ:VICL), sporting a full product pipeline, balance sheet brimming with cash and partnerships with Merck, PMC and Rhone-Poulenc SA (NYSE:RP) division Rhone Merieux also will present. The conference is keynoted by top biotech expert Michael Murphy of the California Technology Stock Letter (www.ctsl.com). On March 15, senior healthcare analyst David Crossen, Ph.D. of Nationsbanc Montgomery Securities keynotes the 4th Informed Investors Bay Area Biotech Forum in Emeryville near San Francisco. Presenting companies include Gilead Sciences (NASDAQ:GILD), which is researching an oral treatment for the flu, and Myriad Genetics (NASDAQ:MYGN) which today announced along with Novartis (NASDAQ:NVTSY) the discovery of a gene that may help companies develop effective treatments for heart disease. Also presenting are anti-aging researcher Geron Corp. (NASDAQ:GERN), partnered with Pharmacia & Upjohn, (NYSE:PNU). and Shaman Pharmaceuticals (NASDAQ:SHMN), working with a division of Merck and others. XOMA Corp. (NASDAQ:XOMA) with a lead compound in Phase III trials rounds out the group. The March 15 Forum is at the Bay Bridge Holiday Inn from 8am-12:45pm. Call Informed Investors (www.informedinvestors.com) at 800/992-4683 for details on both Forums. Cost to attend either Forum is $15 in advance or $20 at the door. Sets of audiocassettes are $25 per Forum or $45 for both, plus $3.95 shipping and handling. "Just as the Cowen Healthcare conference this week in Boston and other institutional events are essential for many analysts and portfolio managers, these Forums are a must for serious biotech investors," said Steve Chanecka, President of Informed Investors. Informed Investors has featured scores of quality companies and industry experts at its Forums since 1993 and represents individual investors who collectively hold an estimated $1.5 billion in investable assets. CONTACT: Informed Investors Bob Taylor/Tim Quast, 916/448-8222 KEYWORD: CALIFORNIA INDUSTRY KEYWORD: MEDICINE BIOTECHNOLOGY BANKING Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com Copyright 1998, Business Wire

To: Andrew H who wrote (17129)	3/10/1998 11:16:00 PM
From: Marcus Halprin	Read Replies (1) \| Respond to of 32384

I'm new here and I'm also an investor in Ligand(a measly 700 shares). I have learned a great deal from Henry and from others as well. There have been some instances of people who have muddied the waters here by posting things that they shouldn't have. One such example is what transpired today in which I will not attempt to go in to. But, I respectfully ask you to stop antagonizing people. You use to submit informative posts about Ligand. Now, almost everything you post is either a personal attack or a put down of someone. I wish you would be kind enough to stop your childish antics, and get back to talking about LGND. I am also surprised that no one else here has politely asked you to stop. I know that other members have asked a certain few to refrain from using a certain tone, but which troubles me is that I don't think anyone has ever asked you stop, which troubles me. I almost get the sense you are Henry's spokesperson since you seem to fight his battles. My message is also for everyone else. Let's try to get a better handle on what is to come for ligand. I'm sorry for intruding but I thought someone should say something. Thank you, Marcus